Bay Area Lyme Ventures invests in Galaxy Diagnostics to advance tick-borne disease testing

2 June 2026 — Bay Area Lyme Ventures has made a strategic investment in Galaxy Diagnostics, alongside a licensing agreement with Virginia Tech for Borrelia peptidoglycan antigen-detection research. CEO Nicole Bell: “We are honored to receive support from Bay Area Lyme Ventures at a critical moment for tick-borne disease diagnostics.”

Source: https://www.bayarealyme.org/blog/bay-area-lyme-ventures-invests-in-galaxy-diagnostics-to-advance-tick-borne-disease-testing/

Albion Trinity Capital is an investor in Galaxy Diagnostics.